Advertisement
U.S. markets open in 3 hours 2 minutes
  • S&P Futures

    5,069.25
    -11.75 (-0.23%)
     
  • Dow Futures

    38,879.00
    -114.00 (-0.29%)
     
  • Nasdaq Futures

    17,882.00
    -33.25 (-0.19%)
     
  • Russell 2000 Futures

    2,048.10
    +4.70 (+0.23%)
     
  • Crude Oil

    78.41
    -0.13 (-0.17%)
     
  • Gold

    2,038.90
    -3.80 (-0.19%)
     
  • Silver

    22.56
    -0.08 (-0.34%)
     
  • EUR/USD

    1.0842
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2740
    0.0000 (0.00%)
     
  • Vix

    13.98
    +0.14 (+1.01%)
     
  • GBP/USD

    1.2658
    -0.0002 (-0.02%)
     
  • USD/JPY

    149.9760
    -0.6570 (-0.44%)
     
  • Bitcoin USD

    62,926.42
    +3,508.89 (+5.91%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,646.30
    +21.32 (+0.28%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

Merck loses bid to revive $2.54 billion patent verdict against Gilead

By Jan Wolfe

Oct 30 (Reuters) - A U.S. appeals court on Wednesday dealt a major blow to Merck & Co Inc as it upheld a ruling that threw out a $2.54 billion jury verdict the drugmaker had won against Gilead Sciences Inc.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit upheld a Delaware judge's determination that the Merck patent at issue in the case, which relates to hepatitis C treatment, should not have been granted.

(Reporting by Jan Wolfe; Editing by Susan Fenton)

Advertisement